Company news

Medexus Pharmaceuticals Inc. news in 2024

Medexus Pharmaceuticals Inc.'s news releases, calls and decks from 2024, newest first.

View company

Medexus and medac Conclude Negotiations to Amend US Treosulfan Agreement, Setting Regulatory Milestone Amounts and Payment Schedule

December 2, 2024

Medexus and pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Trecondyv (treosulfan for injection) in Canada

November 18, 2024

Medexus Announces Strong Fiscal Q2 2025 Results

November 7, 2024

Medexus Schedules Second Fiscal Quarter 2025 Conference Call

October 29, 2024

Medexus Provides Update on Treosulfan NDA Review Process and Extended PDUFA Goal Date

September 16, 2024

Medexus Announces Strong Fiscal Q1 2025 Results

August 7, 2024

Medexus Schedules First Fiscal Quarter 2025 Conference Call

July 30, 2024

Medexus Generates Record Revenue of US$113.1 Million in Fiscal Year 2024

June 25, 2024

Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2024 Conference Call

June 18, 2024

FDA Accepts for Review Treosulfan NDA Resubmission

June 6, 2024

Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada

May 1, 2024

Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

April 2, 2024

FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients

March 26, 2024

Medexus Announces Fiscal Q3 2024 Results

February 7, 2024

Medexus Schedules Third Fiscal Quarter 2024 Conference Call

January 30, 2024

Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine

January 8, 2024

Calls in 2024